Combined synopsis and solicitation
Transcriptomics Sequencing and analysis in Liver Spheroids
75N95025Q00040
National Institutes of Health, National Institutes of Health Nida. Biological Product (except Diagnostic) Manufacturing.
Response deadline
November 22, 2024 at 3:00 PM EST
Closed 709 days ago. Posted November 15, 2024. Scheduled to archive November 23, 2024.
Get the next one like this from National Institutes of Health by email, the day it is posted.Find my opportunities
This one closed in 2024
1 like it is open now in biological product (except diagnostic) manufacturing
- Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Animal and Plant Health Inspection Service, MRPBS Minneapolis MN
Combined synopsis and solicitationNAICS 325414Anywhere in the US12639527R0001Closes in 9 daysNov 10
Description
As published on SAM.gov.
The National Center for Advancing Translational Sciences (NCATS) requires transcriptomics sequencing and analysis in liver spheroids. This requisition is requesting a contract to evaluate the RNA expression in liver toxicity associated with the systemic administration of antisense oligonucleotides (ASOs) in previously tested human, rat and mouse animal models. The project's phase one goal is to develop a predictive model of candidate ASO therapies' safety and acute toxicity.
NCATS is seeking technical support to evaluate the safety and acute liver toxicity of candidate ASOs by checking the gene expression. The results from these studies, in conjunction with existing cell-based assays, will help better predict the safety of future candidate ASOs intended for clinical use. The objective of this contract is to generate proof-of-concept data for evaluating the ability of the 3D liver microtissue platform to predict the hepatoxicity of individual ASOs.
If successful, this will represent a new means to screen ASOs for this type of toxicity that is cheaper, faster, and has high throughput. NCATS is seeking technical support to evaluate the safety and acute liver toxicity of candidate ASOs by checking the gene expression. The results from these studies, in conjunction with existing cell-based assays, will help better predict the safety of future candidate ASOs intended for clinical use.
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
November 15, 2024
Combined synopsis and solicitation
Due November 22, 2024 at 3:00 PM EST. SAM.gov, notice 744ddc5e79274223ad51517e767ff410
Points of contact
- Chandani Hangilipolachandani.hangilipola@nih.gov13014807089